KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Operating Expenses: 2017-2025

Historic Other Operating Expenses for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Sep 2025 value amounting to $117,000.

  • Amneal Pharmaceuticals' Other Operating Expenses fell 88.64% to $117,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 104.77%. This contributed to the annual value of -$96.7 million for FY2024, which is 766.98% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Other Operating Expenses stood at $117,000, which was down 70.00% from $390,000 recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Other Operating Expenses high stood at $13.4 million for Q4 2023, and its period low was -$251.9 million during Q2 2022.
  • Moreover, its 3-year median value for Other Operating Expenses was $117,000 (2025), whereas its average is -$6.9 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Other Operating Expenses plummeted by 31,566.67% in 2021, and later soared by 166.48% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Operating Expenses (Quarterly) stood at -$6.0 million in 2021, then crashed by 234.90% to -$20.1 million in 2022, then soared by 166.48% to $13.4 million in 2023, then slumped by 113.35% to -$1.8 million in 2024, then plummeted by 88.64% to $117,000 in 2025.
  • Its Other Operating Expenses stands at $117,000 for Q3 2025, versus $390,000 for Q2 2025 and $5.1 million for Q1 2025.